The ELM trial (Enhanced Lifestyles for Metabolic Syndrome) is a multi-site research study and TMC has partnered with UMKC School of Medicine to be one of five participating sites in the U.S. ELM offers lifestyle programs focused around food, physical activity, and stress management for people with metabolic syndrome that are committed to making healthy lifestyle choices to improve their health. The ELM multi-site trial investigates how to best help people manage the metabolic syndrome by providing resources to participants through group-based or self-directed support.
What is metabolic syndrome?
Metabolic syndrome is a cluster of conditions that occur together, which increase your risk of heart disease, Type 2 diabetes and stroke.
You must meet 3 of the 5 conditions below for metabolic syndrome:
- High blood pressure or taking blood pressure medication
- High blood sugar, or taking Metformin
- High triglyceride
- Low HDL cholesterol
- Excess body fat around the waist
Contact the study today if you meet the following criteria:
- Meet the definition for metabolic syndrome (mentioned above)
- Are 18 years of age or older
- Are interested in and motivated to eat healthier and move more
- Have no history of heart disease, stroke, COPD, or diabetes
- You are able and willing to commit to participating in a two-year trial
What are the benefits of participating?
Participants are randomly assigned to one of the lifestyle-change programs (self-directed or group-based program) for no cost. Everyone who participates will receive a free Fitbit, nutrition and health education, blood work at no cost, and the satisfaction of helping advance research and treatment for metabolic syndrome.
How to join the ELM trial:
To apply to participate at the Truman Medical Center (TMC)/University of Missouri - Kansas City (UMKC) site location in Kansas City, email ELMtrial@tmcmed.org or call Alex Lyon at (816) 404-4045. This partner site is overseen by Principal Investigator Betty Drees, MD, co-Principal Investigator Jannette Berkley-Patton, PhD, and co-Investigator Matthew Lindquist, DO.
Please visit www.elmtrial.org for further information.